Skip to main content

Pay Bill Portals

Our Tests
Our Services
- - Oncology
    - - SERVICES
        
        NateraCore Services
        
        Pharma Partnership
    - - FOR PATIENTS
        
        Schedule Session with Patient Coordinator
        
        Pricing and Billing Information
        
        Contact Us
    - - FOR CLINICIANS
        
        Schedule Session With Client Services
        
        Oncology Portal
        
        Order a Test Kit
        
        Contact Us
  - Organ Health
    - - SERVICES
        
        NateraCore Services
        
        ProReach
    - - FOR PATIENTS
        
        Schedule a Genetic Information Session
        
        Contact Us
    - - FOR CLINCIANS
        
        Organ Health Portal
        
        Contact Us
  - Women’s Health
    - - SERVICES
        
        NateraCore Services
        
        Constellation
    - - FOR PATIENTS
        
        Schedule a Genetic Information Session
        
        Pricing and Billing Information
        
        Women’s Health Portal
        
        Contact Us
    - - FOR CLINICIANS
        
        Order Tests and Track Status on NateraConnect
        
        View Patient Results on NateraConnect
        
        Contact Us
Patient Resources
- - Oncology
    - - LEARN
        
        Signatera
        Altera
        Empower
        View All Patient Resources
    - - EXISTING PATIENTS
        
        Schedule Blood Draw (Existing Patients)
        
        Schedule Session with Patient Coordinator
        
        Pricing and Billing Information
    - - CONNECT
        
        Contact Us
  - Organ Health
    - - LEARN
        
        Prospera
        Renasight
        View All Patient Resources
    - - EXISTING PATIENTS
        
        Schedule Blood Draw (Existing Patients)
        
        Schedule a Genetic Information Session
    - - CONNECT
        
        Contact Us
  - Women’s Health
    - - LEARN
        
        Horizon
        Panorama
        Empower
        Vistara
        Anora
        Spectrum
        View All Patient Resources
    - - EXISTING PATIENTS
        
        Schedule a Genetic Information Session
        
        Schedule Blood Draw (Existing Patients)
        
        Pricing and Billing Information
        
        Women’s Health Portal
    - - CONNECT
        
        Contact Us
Clinical Resources
- - Oncology
    - - CLINICAL RESOURCES
        
        Order Forms
        
        Signatera
        Signatera Publications
        Altera
        Empower
        View All Clinician Resources
    - - RESEARCH STUDIES
        
        Signatera Research Pipeline
        
        BESPOKE CRC
        
        BESPOKE IO
    - - CONNECT
        
        Oncology Portal
        
        Contact Us
  - Organ Health
    - - CLINICAL RESOURCES
        
        Organ Health Publications
        Prospera
        Renasight
        View All Clinician Resources
    - - RESEARCH STUDIES
        
        ProActive Study
        
        PEDAL Study
        
        Trifecta Study
        
        MOTR Study
    - - CONNECT
        
        Organ Health Portal
        
        Contact Us
  - Women’s Health
    - - CLINICAL RESOURCES
        
        Women’s Health Publications
        Horizon
        Panorama
        Empower
        Vistara
        Anora
        Spectrum
        Natera Academy Provider Education Hub
        View All Clinician Resources
    - - RESEARCH STUDIES
    - - CONNECT
        
        Contact Us
Company
Search for:
Pay Bill

Portals
Search for:

Natera, Inc.

- Altera
- Anora
- Empower
- Horizon
- Panorama
- Prospera
- Renasight
- Signatera
- Spectrum
- Vistara
- Blog
- Videos
- Brochure
- Whitepaper
- Manual
- Poster
- Report
- Study
- Webinars
- Natera Academy

Recent Searches

Home
Signatera
Longitudinal Evaluation of Circulating Tumor DNA (ctDNA) as a Prognostic Biomarker to Detect Minimal Residual Disease (MRD) in Testicular Ca

Longitudinal Evaluation of Circulating Tumor DNA (ctDNA) as a Prognostic Biomarker to Detect Minimal Residual Disease (MRD) in Testicular Ca

Published Date June 4, 2024

Fill form to unlock content

Loading, please wait

Error - something went wrong!

Please fill out form to access this item.

Thank you!

Previous Resource

A targeted panel of actionable high risk hereditary cancer predisposition genes can identify patients with pathogenic/likely pathogenic vari
Next Resource

Trial in Progress: Randomized phase III study comparing suspension or continuation of PD-1 Pathway Blockade for patients with advanced non-s

Related Content

6 days ago
The Tipping Point: How clinically validated MRD testing is transforming patient management in colorectal cancer

Watch Video
9 days ago
Utilization of Circulating Tumor DNA in the Surveillance Setting

Gibbs JN, Dale PS, Weatherall AL. The American Surgeon. 2023

Read More
9 days ago
Correlation between variant allele frequency and mean tumor molecules with tumor burden in patients with solid tumors

Kalashnikova E, Aushev, VA, Malashevich AK, et al. Molecular Oncology. 2023

Read More
9 days ago
Immunologic signatures of response and resistance to nivolumab with ipilimumab in advanced metastatic cancer

Tsimberidou AM, Alayli FA, Okrah K, et al. Journal of Experimental Medicine. 2024

Read More
9 days ago
Combined Transcriptome and Circulating Tumor DNA Longitudinal Biomarker Analysis Associates With Clinical Outcomes in Advanced Solid Tumors

Hernando-Calvo A, Yang SYC, Vila-Casadesús M, et al. JCO Precis Oncol. 2024

Read More
9 days ago
Tumor-informed ctDNA assessment as a valuable prognostic and predictive biomarker in diffuse large B-cell lymphoma

Narkhede M, Tomassetti S, Iqbal M. Front. in Oncol 2024

Read More
9 days ago
Efficacy of PARP inhibitor therapy after targeted BRAF/MEK failure in advanced melanoma

Phillipps J, Nassief G, Morecroft R, et al. NPJ Precision Oncology. 2024

Read More
9 days ago
Early real-world experience monitoring circulating tumor DNA in resected early-stage non–small cell lung cancer

Martin T, Dinerman A, Sudhaman S, et al. J Thorac Cardiovasc Surg. 2024

Read More
9 days ago
Clinical significance of perioperative minimal residual disease detected by circulating tumor DNA in lung cancer patients with a long follow

Ohara S, Suda K, Sudhaman S, et al. JTO Cinical and Research Reports. 2024

Read More
9 days ago
ctDNA as an Adjunct to Posttreatment PET for Head and Neck Cancer Recurrence Risk Assessment

Lele SJ, Adilbay D, Lewis E, et al. Otolaryngology–Head and Neck Surgery. 2024

Read More
9 days ago
Post-surgical ctDNA-based molecular residual disease detection in patients with stage I uterine malignancies

F. Recio, C.S. Scalise, P. Loar et al. Gynecologic Oncology. 2024

Read More
9 days ago
Neoadjuvant atezolizumab plus chemotherapy in gastric and gastroesophageal junction adenocarcinoma: the phase 2 PANDA trial

Verschoor YL, van de Haar J, van den Berg JG, et al. Nat Med. 2024

Read More
9 days ago
A phase Ib feasibility trial of response adapted neoadjuvant therapy in gastric cancer (RANT-GC)

Dayyani F, Smith BR, Nguyen NT, et al. Future Oncol. 2022

Read More
9 days ago
Multi-Institutional Study Evaluating the Role of Circulating Tumor DNA in the Management of Appendiceal Cancers

Belmont E, Bansal VV, Yousef MMG, et al. JCO Precis Oncol. 2024

Read More
9 days ago
Lymph-node-targeted, mKRAS-specific amphiphile vaccine in pancreatic and colorectal cancer: the phase 1 AMPLIFY-201 trial

Pant S, Wainberg ZA, Weekes CD, et al. Nat Med. 2024

Read More
9 days ago
Initial Report: Personalized Circulating Tumor DNA and Survival in Patients with Resectable Pancreatic Cancer

Eckhoff AM, Kanu E, Fletcher A, et al. Ann. Surg. Oncol. 2024

Read More
9 days ago
The Sequencing Conundrum in Localized Pancreatic Adenocarcinoma— Progress or Passive Acceptance?

Pathak P, Weekes CD, Shroff RT. JAMA Oncol. 2024

Read More
9 days ago
Perioperative Modified FOLFIRINOX for Resectable Pancreatic Cancer A Nonrandomized Controlled Trial

Cecchini M, Salem RR, Robert M, et al. JAMA Oncol. 2024

Read More
9 days ago
Association of personalized and tumor-informed ctDNA with patient survival outcomes in pancreatic adenocarcinoma

Botta G, Abdelrahim M, Drengler RL, et al. The Oncologist, 2024

Read More
9 days ago
Circulating tumor DNA status and dynamics predict recurrence in patients with resected extrahepatic cholangiocarcinoma

Yoo C, Jeong H, Jeong JH, et al. J. Hepatol., 2024

Read More

Return to Resource Library

© Natera, Inc.

Our Tests
Our Services
Patient Resources
Clinical Resources
- Resource Library
- Provider Portals
Company
Contact

Natera Licenses
IT Security Compliance
Natera Notice of Data Collection for California Residents
Privacy Practices
Privacy Policy
Terms of Use
Sitemap

The tests described have been developed and their performance characteristics determined by the CLIA-certified laboratory performing the test. The tests have not been cleared or approved by the US Food and Drug Administration (FDA). CAP accredited, ISO 13485 certified, and CLIA certified. © 2024 Natera, Inc. All Rights Reserved.